Shuttle Pharma director Steven Richards resigns

Q: What did Shuttle Pharmaceuticals (SHPH) disclose in this 8-K?

Shuttle Pharmaceuticals disclosed that director Steven Richards resigned from its board, effective August 31, 2025, and that his resignation was not due to disagreements with the company.

Q: Did Steven Richards cite any disagreements with SHPH in his resignation?

No. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals on its operations, policies, or practices.

Q: When did the director resignation at Shuttle Pharmaceuticals occur?

Shuttle Pharmaceuticals reported that Steven Richards resigned on August 31, 2025.

Q: Who signed the Shuttle Pharmaceuticals (SHPH) report about the director resignation?

The report was signed by Christopher Cooper, who is identified as the company’s Interim Chief Executive Officer.

Shuttle Pharmaceuticals Holdings, Inc. reported that Steven Richards resigned as a director of the company on August 31, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. reported that Steven Richards resigned as a director of the company on August 31, 2025. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals regarding its operations, policies, or practices. The report was signed on behalf of the company by Interim Chief Executive Officer Christopher Cooper.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Shuttle Pharmaceuticals (SHPH) disclose in this 8-K?

Shuttle Pharmaceuticals disclosed that director Steven Richards resigned from its board, effective August 31, 2025, and that his resignation was not due to disagreements with the company.

Who resigned from the Shuttle Pharmaceuticals (SHPH) board?

Steven Richards resigned as a director of Shuttle Pharmaceuticals Holdings, Inc.

Did Steven Richards cite any disagreements with SHPH in his resignation?

No. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals on its operations, policies, or practices.

When did the director resignation at Shuttle Pharmaceuticals occur?

Shuttle Pharmaceuticals reported that Steven Richards resigned on August 31, 2025.

Who signed the Shuttle Pharmaceuticals (SHPH) report about the director resignation?

The report was signed by Christopher Cooper, who is identified as the company’s Interim Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/05/2025 - 04:35 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2025

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41488

82-5089826

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.00001 per share		SHPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 31, 2025, Steven Richards resigned as a director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) Mr. Richards’ resignation is not due to any disagreements with the Company on any of its operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Dated: September 5, 2025
	By:	/s/ Christopher Cooper
	Name:	Christopher Cooper
	Title:	Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR